Studies of the immune response to the human immunodeficiency virus (HIV) have been hampered by the antigenic diversity of the HIV envelope protein. In an effort to predict the efficacy of vaccination we have compared the systemic antienvelope antibody response in seronegative volunteers immunized with recombinant gpl60 (either in vaccinia or as soluble protein produced in baculovirus) derived from the HTLV-IIIB strain of HIV-1 and in two laboratory workers accidentally infected with the same strain. 11 of 14 vaccinees responded to immunization by producing anti-gpl60 of similar titer and the same isotype as that seen in the laboratory workers. Four vaccinees also had antibody to the principal neutralizing domain (V3 loop) that was comparable in titer with that seen in the laboratory workers, but the fine specificity of anti-V3 antibody was qualitatively different in the two groups. Antibody that can block the interaction between CD4 and gpl20 was present at comparable levels in three vaccinees and the lab workers. Neutralizing antibody titers were markedly lower in the vaccinees than in the laboratory workers. In seven of the vaccinees, an immunodominant epitope was at amino acid 720-740. Analyses of monoclonal antibodies to this region indicate that they do not neutralize, bind to infected cells, nor function as immunotoxins. Although the anti-gpl60 antibody response was of similar magnitude in both infected and vaccinated individuals, there were important qualitative differences. (J. Clin. Invest. 1993. 
Introduction
The development of an effective vaccine to prevent infection with HIV is a high priority for AIDS research. Several different subunit vaccines based upon the HIV envelope glycoprotein, gp 160, have been tested in humans (1) (2) (3) . Gpl 60 contains well-defined variable and constant regions located on extracellular (gp 120) and transmembrane (gp4 1) domains. Although the gp 160-based subunit vaccines are immunogenic, the ability of the resulting immune response to protect humans against infection is not known. In vitro correlates of humoral immunity such as viral neutralization, inhibition of the interaction between the HIV envelope and its receptor (CD4), and epitope specificity may be predictors of protective antibody responses (4) (5) (6) (7) (8) .
Evaluation of immune responses in vaccinees should include comparisons with those in infected individuals. Because natural infection results in a persistent exposure to a replicating antigen, it may be a most effective way to induce an appropriate and protective immune response (9) . However, such analyses are complicated by the antigenic variability of HIV. Since the infecting strain of HIV is rarely known, sera from infected individuals are usually tested on heterologous laboratory strains of HIV. Some ofthe immunologically most important regions of gp 160 are located in the variable regions. Thus direct comparisons of vaccine responses and immunity arising in natural infection have not yet been performed.
Two laboratory workers have been identified who have been infected with the HTLV-IIIB / LAV strain ofHIV (hereafter referred to as IIIB) (10) . Many of the gp160 subunit vaccines utilize envelope glycoprotein derived from this same strain of HIV (1) (2) (3) 6) . In this paper we compare the antigp 160 antibody responses in the laboratory workers with those from "high responder" vaccinees who were selected because they produced antibody titers comparable to those seen in the laboratory workers. The results indicate that, although antibody of similar titer and isotype was produced in vaccinees and lab workers, there were significant differences in the quality and fine specificity of the antibody response.
Methods
HIVstrains. The vaccines used in this experiment express the envelope protein derived from the LAV (LAI) strain of HIV. The envelope protein of the molecularly cloned HIV isolate NL4-3 is also derived from LAV ( 11 ) . The laboratory workers have been infected with the HTLV-IIIB isolate. Whether LAV and IIIB are distinct isolates remains a matter of contention, but the sequences of the two isolates are highly related. There are small differences in the envelope sequences of these two isolates, as there are between different molecular clones derived from the IIIB isolate. For the sake of consistency, we will refer to these strains as IIIB. Laboratory workers. The first laboratory worker (LWF) has been described elsewhere (10) . The event causing exposure to HIV has not been defined and occurred prior to 1986. LWF is currently healthy with a CD4 cell count < 500/mm3. The second laboratory worker (LWS) became infected in 1990 following exposure of the skin and mucous membranes to concentrated HIVIIIB. LWS is currently healthy, but has received anti-HIV therapy for CD4 cell count < 300. The anonymity of the laboratory workers has been carefully guarded.
Serial clinical, viral, and immune studies have been performed, and details will be published elsewhere (W. A. Blattner, et al., manuscript in preparation). We show samples representing both early (LWS) and late (LWF) postexposure time points.
Vaccination protocols. Vaccination protocols were defined and managed by the National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. All vaccinees were seronegative, healthy volunteers. The first group of vaccinees (amended protocol 002, designated with the letter A) received one or two immunizations of 107-109 pfu/ml vaccinia virus expressing gpI601HIB by bifurcated needle puncture (HIVAC-le; Bristol Myers Squibb/Oncogen, Seattle, WA) (1, 12) followed 2-18 mo later with a booster immunization of 640 Ag of alum adsorbed rgpl6OJJJB (VaxSyn HIV-1; MicroGeneSys, Meriden, CT) (13) . The other group of vaccinees (protocols 003A and 003B, for convenience both are referred to as 003) received three or four immunizations with the alum adsorbed rgp 160, at a dose of either 160 ,gg (vaccinees designated with the letter E) or 640 jg (F vaccinees) (2) . Sera used in this study were selected as representing the highest titers ofanti-gpl 60 antibody produced in vaccinees from these protocols.
Monoclonal antibodies. The following anti-gp 160 mAbs have been described elsewhere: 924, directed against the V3-loop (14, 15); 41.1, recognizing the immunodominant region of gp4l (15, 16) , and F105, which blocks the conformationally dependent CD4 binding site of gpl20 (17) . mAbs B8 and C8 were derived from separate BALB/cJ mice immunized with 10 ,ug of rgpl60 (MicroGeneSys) in complete Freund's adjuvant. Booster immunization of 1-5 Mg rgp 160 in saline was given daily for 4 d before killing of mice and fusion of splenocytes to SP2/0 cells.
Immunoqssays. ELISA were performed using recombinant and peptide antigens as described elsewhere (15) Viral neutralization was performed using a focal infectivity assay (FIA) ( 14, 20) . The molecularly cloned HIV strain NL4-3 was used in the neutralization assays. A pretitered dilution of cell-free virus was mixed with the serum to be tested and incubated for 1 h at 370C. The mixture was then transferred to a monolayer ofCD4+ HeLa cells (cell line 1022). The mixture was incubated on the monolayer for 3 h at 370C. The monolayer was then washed and the cells incubated for 3 d. The cells were fixed with ethanol and stained with a human anti-HIV serum, peroxidase-conjugated anti-human immunoglobulins, and substrate (amino ethyl carbazole; Sigma). Viral foci were identified as multinucleated cells staining with the peroxidase substrate.
Inhibition of the interaction between soluble CD4 (sCD4) and gpl20 was measured by ELISA. gpl20HIIB (American Bio-Technologies) was adsorbed to microtiter plates at 3 jg/ ml. After this, microtiter plates were blocked with PBS/BSA. Then the serum to be tested was added and incubated 1 h at 370C. Following this sCD4-biotin was added to the serum in the microtiter well. sCD4 (American Bio-Technologies) was biotinylated using an N-hydroxy-succinimide ester of biotin (Binding Site, Inc., San Diego, CA), and an appropriate dilution was determined by titration in the absence of sera. After an overnight incubation, the plates were washed and the binding of sCD4 to the microtiter plates was measured with alkaline phosphatase-conjugated avidin (Binding Site, Inc.) and p-nitro phenyl phosphate. The specificity of this assay was demonstrated with mAbs that are known either to block this interaction or to bind to other portions of gp120. Flow cytometry was performed on H9 cells persistently infected with NL4-3 (15) . Cells were incubated with mAbs at 10 jig/ml in PBS/BSA with 0.1% azide for 1 h at room temperature, washed, and incubated with fluorescein conjugated goat anti-mouse immunoglobulins (Organon-Teknika, Malvern, PA). After 1 h, the cells were washed, fixed in 2% paraformaldehyde, and analyzed with single-colorflow cytometry on a Becton Dickinson FACSTARO (Mountain View, CA). Immunotoxins were prepared by conjugating mAbs to ricin A chain and cytotoxicity of the immunotoxins on H9/NL4-3 cells measured as described elsewhere ( 15) . Cells were incubated with the immunotoxin for 72 h and pulsed with 135S] methionine for the final 16 h.
Results
Antibody titers and isotypes. We have measured the amount of anti-gp 160 using an ELISA with recombinant baculoviral gp 160. Table I shows antibody binding in laboratory workers, vaccinees (2 wk following booster immunization), and normals. Laboratory worker sera, from the earliest time point (several months postinfection), have high levels of anti-gp160, as does HIVIG, a pool of immune globulin obtained from multiple HIV-seropositive individuals (21) . Comparable amounts of gpl60-binding antibody were seen in the majority of this selected group of vaccinees. There was no consistent difference between the two immunization protocols. Three 002 vaccinees produced no anti-gpl 60 detectable at this serum dilution, while several of the vaccinees produced antibody levels as high or higher than the lab workers. However, serum antibody titers began to fall in the vaccinees within the next month (not shown). All experiments shown below use the 2 wk post-boost vaccinee samples.
The V3 loop amino acid (AA)' 296-331 is a hypervariable, immunodominant region of gpl20 that serves as a principal target for neutralizing antibody, and plays an important role in HIV cell-tropism (22) (23) (24) . Antibodies to this region were measured using a synthetic peptide that corresponds to AAs 297- 330 (Table I) . Laboratory workers produced high levels of anti-V3 antibody. Four vaccinees from protocol 002 (A28, A 17, A20, and A22) produced anti-V3 in amounts comparable to those seen in the laboratory workers. None of the 003 vaccinees produced measurable anti-V3, even though they had equivalent titers of anti-gp 160 as the laboratory workers. The class and IgG subclass of the anti-gp 160 response were measured by ELISA (Fig. 1) . The predominant response in both the vaccinees and the laboratory workers was IgG, with IgG 1 and IgG3 subclasses predominating. One vaccinee (A17) produced a significant level of serum IgA. The anti-V3 response (only typable in the lab workers) was also of the IgG 1 and IgG3 isotype. Although only the 002 vaccinees are shown in Fig. 1 , similar isotypes were produced by the 003 vaccinees.
Functional measurement ofantibody. We have used a focal infectivity assay to measure the neutralization of cell-free HIV by human sera (Fig. 2) . Since the serum was only present for 3 h during the time of infection of the monolayer cells with cellfree virus, this assay measures only antibody-mediated inhibition of HIV attachment and initial infectious events. Normal sera showed no inhibition of focus formation. Laboratory workers produced high titers of neutralizing antibody, with complete inhibition seen at dilutions as great as 1:500 at some time points. In this assay only two vaccinees (A28 and A22) clearly produced even low titers of neutralizing antibody. A third serum (A17) gave marginal neutralization. Although only five vaccinees from protocol 002 are shown in the figure, we have tested nine 002 and six 003 vaccinees and found that no others had any detectable neutralizing antibody. The neutralization results we have obtained with the 002 vaccinees are comparable with those reported using a different technique by the Central Immunology Laboratory of the NIAID AIDS Vaccine Clinical Trials Network although our actual titers are somewhat lower ( 13) .
Another way in which antibody may protect against HIV is by inhibiting the interaction between gp 120 and its cellular receptor CD4. Recently, both monoclonal and polyclonal antibodies with CD4-gp 120 inhibiting activity have been described and their functional activity demonstrated ( 17, 25 gp4l immunodominant region, AA 575-604 (26) (both), the putative CD4 binding site AA 420-445 (27) (laboratory workers only), and a mid-gp41 region AA 720-740 (28) (vaccinees only). Detailed analyses of the V3 and the mid-gp41 regions are shown below. Fig. 4 shows the fine specificity of the antibody response to V3 peptides. In all 11 samples from the laboratory workers (three ofwhich are shown), peptide 8 was highly immunodominant. This peptide is located at the "tip" of the V3 loop and contains the conserved core sequence GPGRAF. Neutralizing mAb 924 bound to peptide 10. Antibody from vaccinees in protocol 003 predominantly reacted with peptides 5-8 (as exemplified by vaccinee ES, shown in the figure) . In all vaccinees from protocol 002, peptide 11 was a site ofreactivity, but there was also binding to other peptides in the V3 region in a variable pattern. We have tested for antibodies that cross-react with peptides corresponding to the V3 loops (AA 302-322) of 10 heterologous HIV strains. Lab worker sera reacted with peptides corresponding to the MN and RF isolates.
Vaccinees made a major antibody response to the midgp41 region that did not occur in laboratory workers. This is shown in Fig. 5 (Fig. 3) . Positive controls, including sCD4 and mAb F105, inhibited this binding (Fig. 3, top) (18) . The first peptide includes AA 1-12. Each successive peptide was started three AA toward the carboxy terminus (e.g., peptide 2 encompasses AA 4-15), producing a nine-AA overlap. Initial analyses with these pins included mapping mAbs of known epitope specificity and titrations of lab worker and normal sera. Appropriate reactivities were detected with mAbs. It was determined that the best signal-to-noise ratio was obtained using serum at a 1: 1000 dilution. The qualitative nature of the Geysen analyses must be emphasized. Only a single serum was tested at a time. Quantitative comparisons among sera cannot be made.
We tested seven serial samples on LWF, four on LWS. All vaccinees listed in Table I were tested, as were five sera from unimmunized seronegative individuals. There were several regions that were consistently positive in either vaccinees, laboratory workers, or both. These include the V3 loop (both), the Peptide Number Figure 4 . Geysen peptide analysis of the fine specificity of anti-V3 response. Epitope scanning was performed individually on each lab worker, vaccinee, or normal serum. Sera were tested at 1:1000 dilution on a set of immobilized Geysen peptides. Binding was detected with anti-human Ig conjugated to alkaline phosphatase followed by chromogenic substrate. Although all sera were tested against 283 overlapping 12- tory workers. There was no correlation between the production of antibody to this epitope and neutralization.
To study the function of antibodies to this region, we have analyzed two murine mAbs that react with mid gp4 1 peptides: C8 reacts with peptides 5, 6 , and 7 (as numbered in Fig. 5 ), while B8 reacts with 8 and 9. Fig. 6 shows the results of three different analyses with C8 and B8 antibodies. Expression of viral antigens on the surface of HIV-infected cells was examined by flow cytometry (A). The V3 loop (detected with mAb 924) was well expressed, while neither C8 nor B8 bound to the cell surface. Antibody-mediated neutralization of cell-free virus by mAbs is shown in B. While 924 gives 50% inhibition at 3 ,ug/ml, no inhibition was seen at any concentration with either C8, B8, or a mixture of both. As an extremely sensitive test of the ability of antibody C8 to function in the removal of HIV-infected cells, we coupled the antibody to ricin A-chain and tested whether it functioned as an immunotoxin ( 15) . C compares the C8 immunotoxin with another anti-gp41 mAb (41.1 ) coupled to ricin A chain. Antibody 41.1 recognized a surface-exposed epitope near the amino terminus of gp4 1 and was highly effective in killing infected cells at concentrations as low as 0.3 tg/ml; there was no significant difference between C8 and the irrelevant control antibody T7 at any dose. There was marginal suppression by C8 immunotoxin at the highest concentration (10 Atg/ml). This was a reproducible phenomenon, but it always occurred in the dose range where the irrelevant antibody gave nonspecific suppression. The experiments shown in Fig. 6 were performed with one strain ofHIV. The C8 immunotoxin was also tested on MN and SF2 isolates and found ineffective. The data obtained with mAbs C8 and B8 suggest that antibody to the mid-gp4 1 epitope is not likely to have a functional effect. These data contradict those of other studies of this epitope, which suggest that this is a weak, but cross-reactive, neutralizing epitope (28-32).
HIV Antibody Responses 1991 In this paper, we compared systemic antibody responses following immunization and natural infection. We minimized effects due to HIV variation by using sera from laboratory workers infected with the same strain of HIV (HTLV-IIIB/ LAV) used to prepare the vaccine. The laboratory worker sera were compared with selected high titer vaccinee sera. The analyses indicate that current immunization protocols can induce antibodies to important epitopes, but there were significant differences in the quality and fine specificity of the antibody response in vaccination and natural infection.
Natural infection should be an excellent route for the induction of immunity for several reasons (9) . It results in prolonged exposure to a replicating antigen. Infection results in exposure to an immunizing antigen that is identical to the target antigen; all current HIV vaccines differ in some way from Immunotoxin function was measured as the suppression of protein synthesis in HIV-infected cells ([35SI methionine incorporation). mAbs used were: T7 an irrelevant control mAb, 924 directed against the V3 loop, 41.1 which binds the gp4 1 immunodominant region, C8 and B8 which recognize epitopes within the mid-gp4l region. All assays were performed using the molecularly cloned HIV NL4-3. the true virus. While it is clear that natural infection does not result in immunity that completely protects against disease progression once infection has occurred, evidence supports the idea that natural infection does protect against a later reinfection with HIV. For example, there have been no documented cases where two distinctly different HIV-1 isolates have been obtained from a single individual, although the technology exists to identify such isolates by signature sequences. Thus, comparison to the immunity arising in natural infection is likely to be useful in identifying parameters that may define immunity that protects against infection with HIV.
Although several vaccinee sera contained anti-gp 160 antibodies of similar titer and isotype to those of lab worker sera, there were significant differences in the specificity and functional activities ofthe antibody produced. Lab worker sera neutralized in high titer; sera from vaccinees did not. The epitope specificity ofthe antibody was also different. Anti-V3 bound to different portions of the loop. The vaccinees produced a large response to an epitope in mid-gp41 (AA 720-740), while the lab workers did not. Our studies with mAbs suggest that this latter epitope may be functionally irrelevant (Fig. 6) .
Interestingly, we also found that immunization protocol influenced the quality of the antibody. Both protocols used recombinant gp 160. However, in protocol 002 primary immunization was with recombinant gp 60-vaccinia virus vaccine (HIVAC-le) (1, 12), while in protocol 003 subjects received alum precipitated purified rgp 160 (VaxSyn HIV-1) as the primary immunization (2) . Vaccinees in both protocols were boosted with purified gpl6O. In our assays, the only subjects who produced significant amounts of anti-V3, neutralizing, or CD4-gp 120 inhibiting antibodies were from the 002 protocol. The 002 protocol also resulted in most antibody directed against the mid-gp4 1 epitope, both in terms of the magnitude of the response and the proportion of vaccinees producing the antibody. There may also have been a difference in the fine specificity of the anti-V3 response in the two protocols, but these studies were hampered by the low titers of anti-V3 in the 003 vaccinees.
The use of synthetic peptides to map the epitope specificity of the antibody response must be approached with caution ( 18, 34 (14, 22, 23, 35, 36) and can prevent experimental infection (8) . Because V3 synthetic peptides can induce neutralizing antibody, it is thought that the V3 neutralizing determinant may be a linear epitope. In contrast, CD4-gpl 20 inhibiting antibody may be conformational (17, 25) , although several inhibiting mAbs have been mapped to a specific epitope (AA 420-445) (27, 37) . Neutralizing antibodies have been reported against other specific regions of gp120 (38, 39) , but these may represent CD4-gpl 20 inhibiting antibodies. Neutralization has also been reported with anti-gp4 1, in particular with antibodies to the mid-gp4l epitope AA 720-740 (28) (29) (30) (31) and to a conserved epitope at AA 672-677 (40) . The mechanism whereby antigp41 antibodies might neutralize is not known. We have used an FHA to measure neutralization ofHIV infection by antibody (14, 20) . Because the antibody was present only during the incubation of the target cells with cell free virus, this assay measured only early neutralization events, and not such later events as inhibition of syncytia formation or secretion of virus by infected cells. Thus our assay may only have measured a subset of neutralizing antibodies. In our studies, we found that fine specificity of anti-V3 correlated best with the production of neutralizing antibody. Infection resulted in antibody that reacted with a peptide corresponding to the "tip" of the V3 loop and high titers of neutralizing antibody, while sera from some 002 vaccinees who had equal titers of antibody to the whole loop, but bound to other peptides, neutralized only weakly. However, one 002 vaccinee (A20) produced high titer anti-V3 with antibody binding the peptide corresponding to the "tip" and yet had no neutralizing antibody. The three vaccinees who produced neutralizing antibody (A28, A17, and A22) were also the only vaccinees who produced CD4-gp 120 inhibiting antibody. There was no evidence to suggest any correlation between neutralization and antibody to the midgp41 epitope. It is likely that the neutralizing antibody response results from the additive effect ofantibodies to several different specificities.
In light of the impressive response of the 002 vaccinees to the mid-gp4l epitope, it is extremely important to determine the antiviral capacity ofantibody to this epitope. Our data with mAbs C8 and B8 indicate that antibody to this epitope is unlikely to inhibit HIV. These analyses were performed with three different strains of HIV and with both cell-free and cellassociated HIV. Our mAb analyses are also consistent with the low degree or absence of neutralization seen in vaccinee sera with high titers ofantibody to the mid-gp4 1 epitope. Most structural predictions suggest this epitope lies on the cytoplasmic side of the cell membrane (26) . Yet there are persistent reports that this epitope has functional significance (28) (29) (30) (31) (32) . At the very best, only weak neutralizing responses were obtained following immunization with peptide corresponding to this epitope. It is possible that differences in HIV isolates, cell lines, stringency of experimental criteria, or laboratory artifacts could explain the discrepancy with previous reports. Further studies ofthe antibody response to the mid-gp4l, AA 720-740, epitope are needed to resolve this issue.
Having documented that immunization of humans with certain rgp 160 vaccines may result in low titers of antibody to important antigenic structures and higher titers to possibly irrelevant epitopes, we should ask if the irrelevant response somehow suppresses the development of a more appropriate response? Several mechanisms could account for feedback inhibition of the antibody response. The regulation of the immune response by antibody to the antigen is a well-described phenomenon (41, 42) . Alternatively, idiotype suppression could occur since anti-HIV antibodies to different viral structures have been shown to share a cross-reactive idiotype (43) . This issue is of practical importance, since a vaccine construction lacking the mid-gp4 l epitope might yield more neutralizing antibody.
The data presented in this paper suggest that the neutralizing antibody response obtained with these vaccination protocols fell short of a maximal response. Because we do not know what degree of immunity confers protection, we cannot say that these protocols are inadequate. Further refinements in immunization protocols may lead to antibody that more closely approximates the standard set by natural infection. It will be important to analyze systemic antibody responses resulting from immunization with other IIIB-based vaccine protocols in the manner described here. Of particular interest will be the results obtained following immunization with rgp 120. This subunit lacks both the irrelevant mid-gp41 epitope and potential targets of enhancing antibody (33) , and immunization with gpl2O, but not gpl6O, has been shown to prevent HIV infection of chimpanzees (6) . Protocols combining priming with vaccinia-gpl60 (or gpl20) followed by boosting with soluble gp 120 might also be tried.
The continuing rapid spread of AIDS through the developing world has led to a feeling of urgency in initiating vaccine efficacy trials (44) . Such trials are likely to be costly, involve large control populations, and require long periods ofobservation before a vaccine effect can be demonstrated. It is imperative that any efficacy trial be performed with the most effective vaccination protocol(s). Intensive study of the in vitro correlates of immunity obtained in already ongoing small-scale vaccination protocols is needed to aid in choosing candidate vaccines for larger efficacy trials.
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